Study to Assess the Efficacy and Safety of Different Doses of BIM 23A760 in Patients With Carcinoid Syndrome
The purpose of the protocol is to assess the efficacy and safety of BIM 23A760 on patient’s overall satisfaction in terms of symptom relief (diarrhoea and/or flushes) in patients with carcinoid syndrome after 24 weeks of treatment.
Study to Assess the Efficacy and Safety of Different Doses of BIM 23A760 in Patients With Carcinoid Syndrome
- 04 Décembre 2024 - 1 mins read
The purpose of the protocol is to assess the efficacy and safety of BIM 23A760 on patient’s overall satisfaction in terms of symptom relief (diarrhoea and/or flushes) in patients with carcinoid syndrome after 24 weeks of treatment.
Related Clinical Trials
04 Décembre 2024
1 mins read
A Long-Term Study of Elafibranor in Adult Participants with Primary Biliary Cholangitis
04 Décembre 2024
1 mins read
A Study to Assess Safety and Effectiveness of Elafibranor in Adult Participants with Primary Sclerosing Cholangitis.
04 Décembre 2024
1 mins read
A Study to Evaluate the Effect of Food on the Level of Circulating Elafibranor in Healthy Participants after Intake of a Single Tablet
04 Décembre 2024
1 mins read
Study to Compare the Level of Elafibranor in Blood after Repeat Administration in Japanese and non-Asian Healthy Participants
04 Décembre 2024
1 mins read
A Rollover Study to Further Evaluate the Safety and Efficacy of Palovarotene Capsules in Male and Female Participants Aged ?14 Years With Fibrodysplasia Ossificans Progressiva...
04 Décembre 2024
1 mins read
Effects of maintenance cabozantinib+BSC versus BSC in children and AYA with osteosarcoma.
04 Décembre 2024
2 mins read
A study to evaluate the effectiveness and safety of Dysport® for the prevention of episodic migraine in adults
04 Décembre 2024
2 mins read
A study to evaluate the effectiveness and safety of Dysport® for the prevention of chronic migraine in adults
04 Décembre 2024
1 mins read
A Study to Compare the Safety and Efficacy of Dysport® and Botox® in Adults With Upper Limb Spasticity.
04 Décembre 2024
2 mins read